Tandel Jinal J, Polra Rutoo V, Parmar Dharmesh, Srivastava Priyanka, Panchal Rushikumar, Nair Pragya A
Department of Dermatology, Venereology and Leprosy, Shree Krishna Hospital, Bhaikaka University, Karamsad, Gujarat, India.
Department of Internal Medicine, Shree Krishna Hospital, Bhaikaka University, Karamsad, Gujarat, India.
Indian Dermatol Online J. 2022 Oct 31;13(6):757-764. doi: 10.4103/idoj.idoj_168_22. eCollection 2022 Nov-Dec.
Chemotherapy and radiation therapy given to treat internal malignancies may cause cutaneous, hair, nail, and oral mucosal changes. The present study is an effort to know the pattern of cutaneous drug reactions with chemo and radiotherapy.
Patients of internal malignancies with skin lesions attending the dermatology and oncology OPD/ward were recruited after taking their written consent in vernacular language. A detailed history of skin lesions, malignancies, and treatment was taken. Clinical examination was carried out. Relevant investigations and biopsy were carried out as and when required. Being a descriptive study, age group and gender-wise frequency and percentage were calculated for the treatment of malignancies and dermatosis.
The study included 150 patients with 28 different types of internal malignancies, of which 127 (84.66%) patients were treated, 45 (35.43%) treated exclusively with chemotherapy, 16 (12.59%) with exclusive radiation therapy, and 66 (51.96%) with combined chemo and radiation therapy. Total 111 (87.41%) patients received chemotherapy and 82 (64.56%) patients received radiation therapy. Most common internal malignancy was breast carcinoma in 43 (28.67%) cases. Most common chemotherapeutic agent given was paclitaxel to 33 (29.73%) patients. Most common dermatosis associated with exclusive chemotherapy was hand-foot syndrome in 7 (15.55%) cases and with exclusive radiation therapy was radiation dermatitis in 8 (50%) cases.
The study was useful in understanding various chemo and radiation therapy-associated dermatosis so that early interventions can be done to prevent further treatment-related adverse effects.
Small sample size and inability of pinpointing a single drug as the side effect.
用于治疗体内恶性肿瘤的化疗和放疗可能会导致皮肤、毛发、指甲和口腔黏膜发生变化。本研究旨在了解化疗和放疗引起的皮肤药物反应模式。
在获得患者用当地语言签署的书面同意书后，招募了皮肤科和肿瘤科门诊/病房中患有皮肤病变的体内恶性肿瘤患者。详细询问了皮肤病变、恶性肿瘤和治疗的病史。进行了临床检查。根据需要进行了相关检查和活检。作为一项描述性研究，计算了治疗恶性肿瘤和皮肤病的年龄组及按性别划分的频率和百分比。
该研究纳入了150例患有28种不同类型体内恶性肿瘤的患者，其中127例（84.66%）接受了治疗，45例（35.43%）仅接受化疗，16例（12.59%）仅接受放疗，66例（51.96%）接受了化疗和放疗联合治疗。总共有111例（87.41%）患者接受了化疗，82例（64.56%）患者接受了放疗。最常见的体内恶性肿瘤是乳腺癌，共43例（28.67%）。最常用的化疗药物是紫杉醇，有33例（29.73%）患者使用。与单纯化疗相关的最常见皮肤病是手足综合征，有7例（15.55%）；与单纯放疗相关的最常见皮肤病是放射性皮炎，有8例（50%）。
该研究有助于了解各种化疗和放疗相关的皮肤病，以便能够尽早进行干预，预防进一步的治疗相关不良反应。
样本量小，且无法确定单一药物为副作用来源。
